Cytomegalovirus Infection After Chimeric Antigen Receptor T‐Cell Therapy or Bispecific Antibody Treatment for Hematologic Malignancies
Transplant Infectious Disease · 2025
DOI: 10.1111/tid.70138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Juhui Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Hematologic Neoplasms, Antibodies, Bispecific, Immunotherapy, Adoptive. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea from the Ministry of Science and ICT, South Korea.
Abstract (Originalsprache)
Background
Limited data exists on the incidence of CMV infections after chimeric antigen receptor (CAR) T‐cell or bispecific antibody (BsAb) therapy for hematologic malignancies.
Methods
We reviewed medical records of patients with hematologic malignancies treated with CAR T‐cells or BsAbs between July 2018 and October 2024 in a tertiary hospital in Seoul, South Korea. CMV infections were detected using CMV DNA qPCR assays performed within 180 days after CAR T‐cell infusion or the last BsAb treatment. Secondary outcomes were the occurrence of clinically significant CMV infections (CS‐CMVi) and end‐organ diseases.
Results
Of 179 patients, 76 (42%) received CAR T‐cell therapy, and 103 (58%) received BsAb therapy. The incidence of CMV infection was 62% in BsAb recipients, and 43% in CAR T‐cell recipients. Two (6.1% of total CMV infections) CAR T‐cell recipients had CS‐CMVi, and 1 (3.0%) developed possible CMV pneumonia. In the BsAb group, 10 (16% of total CMV infections) patients received antiviral therapy, and 4 (6.3%) had end‐organ diseases. Receiving three or more previous systemic chemotherapy regimens in the CAR T‐cell group was associated with increased CMV infection risks (HR 4.7, 95% CI 1.88–11.8, p < 0.001), and older age in the BsAb group had a trend toward having more CMV infection (HR 1.02, 95% CI 1.00–1.05, p = 0.06).
Conclusion
Approximately 43% and 62% of patients receiving CAR T‐cell and BsAb therapy had CMV infection, with 1%–4% developing CMV diseases. Effective strategies for preventing CMV infections in these patients are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Förderung
- National Research Foundation of Korea from the Ministry of Science and ICT, South Korea
Zitieren
APA
Han, J., Lim, S. Y., Hyung, J., Cho, H., Yoon, D. H., & Kim, S. H. (2025). Cytomegalovirus Infection After Chimeric Antigen Receptor T‐Cell Therapy or Bispecific Antibody Treatment for Hematologic Malignancies. Transplant Infectious Disease. https://doi.org/10.1111/tid.70138
Vancouver
Han J, Lim SY, Hyung J, Cho H, Yoon DH, Kim SH. Cytomegalovirus Infection After Chimeric Antigen Receptor T‐Cell Therapy or Bispecific Antibody Treatment for Hematologic Malignancies. Transplant Infectious Disease. 2025. doi:10.1111/tid.70138
BibTeX
@article{Han2025,
author = {Han, Juhui and Lim, So Yun and Hyung, Jaewon and Cho, Hyungwoo and Yoon, Dok Hyun and Kim, Sung-Han},
title = {Cytomegalovirus Infection After Chimeric Antigen Receptor T‐Cell Therapy or Bispecific Antibody Treatment for Hematologic Malignancies},
journal = {Transplant Infectious Disease},
year = {2025},
doi = {10.1111/tid.70138}
}
EUVIMED